The Development of a Metabolomic Test to Diagnose and Quantify Pancreatic Exocrine Insufficiency (The DETECTION Study) (DETECTION)
Pancreatic Exocrine Insufficiency
About this trial
This is an interventional diagnostic trial for Pancreatic Exocrine Insufficiency focused on measuring exocrine insufficiency, pancreatic cancer, metabolomics, metabolites, chronic pancreatitis, cystic fibrosis
Eligibility Criteria
Inclusion Criteria: (for main pancreatic cancer cohort) PDAC PEI (as defined by breath test) Tolerating oral diet Inclusion Criteria: (for CF cohort) CF PEI (as defined by breath test) Tolerating oral diet Inclusion Criteria: (for CP cohort) CP PEI (as defined by breath test) Tolerating oral diet Exclusion Criteria (all arms): No other GI conditions For each arm no evidence of the other arm conditions For health controls, no history of CP, CF or pancreatic cancer No GI surgery (except pancreatic resection in the pancreatic cancer cohort) Unable to consent Unable to travel to UHB for testing Prognosis < 2months Performance status 2+
Sites / Locations
- University Hospitals Birmingham NHS Foundation TrustRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Other
Other
Other
Pancreatic cancer (main cohort)
Sub-study cohorts: Chronic pancreatitis, cystic fibrosis, NET patients on SSAs
Dosing arm
investigation of PEI and the metabolome of patients with pancreatic cancer in the fed and fasted state
investigation of PEI and the metabolome of patients with other causes of PEI in the fed and fasted state
Investigation metabolome of patients pre and post initiation of PERT as part of their PEI care